Comparative outcome analysis of hydroxychloroquine/chloroquine, remdesivir and standard of care treatment against COVID-19 infection

Authors

  • Vikas Kumar Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
  • Sumit Kumar Mahato Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20205550

Keywords:

nCoV-19, COVID-19, Hydroxychloroquine/chloroquine, Remdesivir, Standard of care

Abstract

This study aimed to compare the efficacy and safety of hydroxychloroquine/chloroquine (HCQ/CQ), remdesivir and standard of care treatment (SOC) in patients with nCoV-19 based on the RCTs available in the literature. We conducted a cumulative review of all the RCTs published for the treatment of nCoV-19. Analysis for odds of patient recovery on HCQ/CQ, remdesivir and SOC treatment was accomplished and recovery was expressed as undetectable viral RNA levels. Total sample size in our analysis was 978 from six RCTs, in which nCoV-19 positive patients treated with HCQ/CQ, remdesivir and SOC were 166,560 and 252, respectively. SOC treatment showed increase in 2-fold of patients’ recovery as compared to the HCQ/CQ group (p=0.0006). Further, patients reported 1.5-3-fold increase in adverse events in remdesivir and HCQ/CQ group as compared to SOC group (p=0.0016 and p<0.0001). Our finding suggests remdesivir or HCQ/CQ ensures no benefit over SOC treatment, which may be attributed to the adverse events exhibited by remdesivir, or inefficacy of HCQ/CQ.

Author Biographies

Vikas Kumar, Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India

Senior Resident, Department of pharmacology. All India Institute of Medical Sciences

 

Sumit Kumar Mahato, Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India

Senior Resident, department of pharmacology. All India Institute of Medical Sciences

References

Available at: https://www.who.int/newsroom/detail/27-04-2020-who-timeline---covid-19. Accessed on 10 August 2020.

Available at: http://www.who.int/docs/default source/coronaviruse/situation-reports/20200620- covid-19-sitrep-152.pdf?sfvrsn=83aff8ee_2. Accessed on 10 August 2020.

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;323(18):1824-36.

Zheng S, Fan J, Yu F. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, retrospective cohort study. BMJ. 2020;369:m1443.

Hamid S, Mir MY, Rohela GK. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics). New Microbes New Infect. 2020;35:100679.

Borba MGS, Val FFA, Sampaio VS. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020;3:e208857.

Cao B, Wang Y, Wen D. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382:1787-99.

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569-78.

Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020;383(19):1827-37.

Huang M, Tang T, Pang P, Li M, Ma R, Lu J et al. Treating COVID-19 with Chloroquine. J Mol Cell Biol. 2020;12:322-5.

Gao J, Tian Z and Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72-3.

Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:56(1):105949.

Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe F et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet. 2016;388:498-503.

Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020;382:929-36.

Team C-I. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat Med. 2020;26(6):861-8.

Downloads

Published

2020-12-23

How to Cite

Kumar, V., & Mahato, S. K. (2020). Comparative outcome analysis of hydroxychloroquine/chloroquine, remdesivir and standard of care treatment against COVID-19 infection. International Journal of Basic & Clinical Pharmacology, 10(1), 122–126. https://doi.org/10.18203/2319-2003.ijbcp20205550

Issue

Section

Systematic Reviews